The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

Jutzi, 2013, Introduction en Suisse de l'inactivation des agents pathogènes pour les concentrés plaquettaires, Forum Med Suisse, 13, 222, 10.4414/fms.2013.01437 Hoffmeister, 2003, The clearance mechanism of chilled blood platelets, Cell, 112, 87, 10.1016/S0092-8674(02)01253-9 Jansen, 2012, Desialylation accelerates platelet clearance after refrigeration and initiates GPIbalpha metalloproteinase-mediated cleavage in mice, Blood, 119, 1263, 10.1182/blood-2011-05-355628 Hillyer, 2003, Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine, Hematology Am Soc Hematol Educ Program, 575, 10.1182/asheducation-2003.1.575 Lin, 1997, Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light, Transfusion, 37, 423, 10.1046/j.1537-2995.1997.37497265344.x Alter, 2008, The hazards of blood transfusion in historical perspective, Blood, 112, 2617, 10.1182/blood-2008-07-077370 Bryant, 2007, Pathogen inactivation: the definitive safeguard for the blood supply, Arch Pathol Lab Med, 131, 719, 10.5858/2007-131-719-PITDSF Stramer, 2009, Emerging infectious disease agents and their potential threat to transfusion safety, Transfusion, 49, 1S, 10.1111/j.1537-2995.2009.02279.x Klein, 2007, Pathogen inactivation: making decisions about new technologies. Report of a consensus conference, Transfusion, 47, 2338, 10.1111/j.1537-2995.2007.01512.x Webert, 2008, Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies, Transfus Med Rev, 22, 1, 10.1016/j.tmrv.2007.09.001 Corash, 2004, Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease, Bone Marrow Transplant, 33, 1, 10.1038/sj.bmt.1704284 Grass, 1998, Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA, Blood, 91, 2180, 10.1182/blood.V91.6.2180 Ciaravino, 2003, The role of toxicology assessment in transfusion medicine, Transfusion, 43, 1481, 10.1046/j.1537-2995.2003.00544.x Cao, 2008, LC–MS/MS for the detection of DNA interstrand cross-links formed by 8-methoxypsoralen and UVA irradiation in human cells, Anal Chem, 80, 2932, 10.1021/ac7023969 Lai, 2008, Quantitative analysis of DNA interstrand cross-links and monoadducts formed in human cells induced by psoralens and UVA irradiation, Anal Chem, 80, 8790, 10.1021/ac801520m Lin, 2004, Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria, Transfusion, 44, 1496, 10.1111/j.1537-2995.2004.04125.x Lin, 2005, Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light, Transfusion, 45, 580, 10.1111/j.0041-1132.2005.04316.x Wollowitz, 2001, Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma, Semin Hematol, 38, 4, 10.1016/S0037-1963(01)90118-0 Marschner, 2011, Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light, Transfus Med Hemother, 38, 8, 10.1159/000324160 Goodrich, 2010, Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products, Biologicals, 38, 20, 10.1016/j.biologicals.2009.10.016 Mohr, 2009, A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light, Transfusion, 49, 2612, 10.1111/j.1537-2995.2009.02334.x Sandgren, 2011, In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method, Vox Sang, 101, 35, 10.1111/j.1423-0410.2010.01454.x Prowse, 2013, Component pathogen inactivation: a critical review, Vox Sang, 104, 183, 10.1111/j.1423-0410.2012.01662.x Lozano, 2013, Pathogen inactivation: coming of age, Curr Opin Hematol, 20, 540, 10.1097/MOH.0b013e328365a18f Klein, 2009, Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop, Transfusion, 49, 1262, 10.1111/j.1537-2995.2009.02210.x Rasongles, 2009, Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion, Transfusion, 49, 1083, 10.1111/j.1537-2995.2009.02111.x Hauser, 2014, Hepatitis E transmission by transfusion of Intercept blood system-treated plasma, Blood, 123, 796, 10.1182/blood-2013-09-524348 Prudent, 2014, LC–MS/MS analysis and comparison of oxidative damages on peptides induced by pathogen reduction technologies for platelets, J Am Soc Mass Spectrom, 25, 651, 10.1007/s13361-013-0813-8 Prudent, 2014, Proteome changes in platelets after pathogen inactivation — an interlaboratory consensus, Transfus Med Rev, 28, 72, 10.1016/j.tmrv.2014.02.002 Weyrich, 2009, Protein synthesis by platelets: historical and new perspectives, J Thromb Haemost, 7, 241, 10.1111/j.1538-7836.2008.03211.x Thon, 2007, Translation of glycoprotein IIIa in stored blood platelets, Transfusion, 47, 2260, 10.1111/j.1537-2995.2007.01455.x Schubert, 2010, De novo protein synthesis in mature platelets: a consideration for transfusion medicine, Vox Sang, 99, 112, 10.1111/j.1423-0410.2010.01333.x Rollini, 2012, Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease, Platelets, 23, 537, 10.3109/09537104.2012.704649 Harrison, 2009, Screening tests of platelet function: update on their appropriate uses for diagnostic testing, Semin Thromb Hemost, 35, 150, 10.1055/s-0029-1220323 Hayward, 2008, Diagnostic approach to platelet function disorders, Transfus Apher Sci, 38, 65, 10.1016/j.transci.2007.12.009 Stroncek, 2007, Platelet transfusions, Lancet, 370, 427, 10.1016/S0140-6736(07)61198-2 Panzer, 2011, Methods for testing platelet function for transfusion medicine, Vox Sang, 101, 1, 10.1111/j.1423-0410.2011.01467.x Kehrel, 2013, State of the art in platelet function testing, Transfus Med Hemother, 40, 73, 10.1159/000350469 Chavarin, 2011, In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System), Vox Sang, 100, 247, 10.1111/j.1423-0410.2010.01389.x Bochsen, 2011, The influence of platelets, plasma and red blood cells on functional haemostatic assays, Blood Coagul Fibrinolysis, 22, 167, 10.1097/MBC.0b013e3283424911 Kattlove, 1972, The effect of cold on platelets. II. Platelet function after short-term storage at cold temperatures, Blood, 40, 688, 10.1182/blood.V40.5.688.688 Rinder, 2003, In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function?, Transfusion, 43, 2, 10.1046/j.1537-2995.2003.00261.x Cardigan, 2005, Current methods of assessing platelet function: relevance to transfusion medicine, Vox Sang, 88, 153, 10.1111/j.1423-0410.2005.00618.x van Rhenen, 2000, Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats, Vox Sang, 79, 206, 10.1046/j.1423-0410.2000.7940206.x Murphy, 1994, In vitro assessment of the quality of stored platelet concentrates. The BEST (Biomedical Excellence for Safer Transfusion) Task Force of the International Society of Blood Transfusion, Transfus Med Rev, 8, 29, 10.1016/S0887-7963(94)70095-X Holme, 1998, Storage and quality assessment of platelets, Vox Sang, 74, 207, 10.1111/j.1423-0410.1998.tb05422.x Middelburg, 2013, Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates, Transfusion, 53, 1780, 10.1111/trf.12001 Picker, 2004, Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation, Transfusion, 44, 320, 10.1111/j.1537-2995.2003.00590.x Bruchmuller, 2005, Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets, Platelets, 16, 441, 10.1080/09537100500129300 Moog, 2004, In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days, J Clin Apher, 19, 185, 10.1002/jca.20025 Janetzko, 2004, Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets, Vox Sang, 86, 239, 10.1111/j.0042-9007.2004.00419.x Isola, 2006, In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set, Vox Sang, 90, 128, 10.1111/j.1423-0410.2005.00723.x Jansen, 2004, Functional characteristics of photochemically treated platelets, Transfusion, 44, 313, 10.1111/j.1537-2995.2003.00588.x Snyder, 2004, Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light, Transfusion, 44, 1732, 10.1111/j.0041-1132.2004.04145.x Apelseth, 2007, In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage, Transfusion, 47, 653, 10.1111/j.1537-2995.2007.01167.x Wang, 1999, Flow cytometric analysis of platelet function in stored platelet concentrates, Transfus Sci, 20, 129, 10.1016/S0955-3886(99)00022-3 Hagberg, 2000, Apheresis-induced platelet activation: comparison of three types of cell separators, Transfusion, 40, 182, 10.1046/j.1537-2995.2000.40020182.x Vetlesen, 2005, Platelet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions, Transfusion, 45, 1349, 10.1111/j.1537-2995.2005.00218.x Tynngard, 2008, Effects of intercept pathogen inactivation on platelet function as analysed by free oscillation rheometry, Transfus Apher Sci, 38, 85, 10.1016/j.transci.2007.12.012 Lozano, 2007, Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7days: assessment of hemostatic function under flow conditions, Transfusion, 47, 666, 10.1111/j.1537-2995.2007.01169.x Picker, 2009, Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies, Transfusion, 49, 1224, 10.1111/j.1537-2995.2009.02092.x Kenet, 1998, Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients, Br J Haematol, 101, 255, 10.1046/j.1365-2141.1998.00690.x Osende, 2001, Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition, Circulation, 103, 1488, 10.1161/01.CIR.103.11.1488 Cazenave, 2004, Preparation of washed platelet suspensions from human and rodent blood, Methods Mol Biol, 272, 13 Hechler, 2013, Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation, Transfusion, 53, 1187, 10.1111/j.1537-2995.2012.03923.x Shrivastava, 2009, The platelet storage lesion, Transfus Apher Sci, 41, 105, 10.1016/j.transci.2009.07.002 Cognasse, 2008, Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment, Transfusion, 48, 809, 10.1111/j.1537-2995.2008.01655.x Infanti, 2011, Pathogen-inactivation of platelet components with the INTERCEPT Blood System: a cohort study, Transfus Apher Sci, 45, 175, 10.1016/j.transci.2011.07.013 Cazenave, 2011, Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period, Transfusion, 51, 622, 10.1111/j.1537-2995.2010.02873.x de Wildt-Eggen, 2000, Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study, Transfusion, 40, 398, 10.1046/j.1537-2995.2000.40040398.x Osselaer, 2009, Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use, Transfusion, 49, 1412, 10.1111/j.1537-2995.2009.02151.x Osselaer, 2008, An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment, Vox Sang, 94, 315, 10.1111/j.1423-0410.2007.01035.x Janetzko, 2005, Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set, Transfusion, 45, 1443, 10.1111/j.1537-2995.2005.00550.x Kerkhoffs, 2010, Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction, Br J Haematol, 150, 209 Lozano, 2011, A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7d prior to transfusion, Br J Haematol, 153, 393, 10.1111/j.1365-2141.2011.08635.x McCullough, 2004, Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial, Blood, 104, 1534, 10.1182/blood-2003-12-4443 Sigle, 2013, Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components, Transfusion, 53, 1788, 10.1111/j.1537-2995.2012.03959.x van Rhenen, 2003, Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial, Blood, 101, 2426, 10.1182/blood-2002-03-0932 Daly, 1980, Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations, JAMA, 243, 435, 10.1001/jama.1980.03300310023016 Slichter, 2010, Dose of prophylactic platelet transfusions and prevention of hemorrhage, N Engl J Med, 362, 600, 10.1056/NEJMoa0904084 Cook, 2013, Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations, Transfusion, 53, 1843, 10.1111/j.1537-2995.2012.03951.x Corash, 2011, Evaluation of platelet transfusion clinical trials, Br J Haematol, 153, 529, 10.1111/j.1365-2141.2010.08413.x Dumont, 2002, Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study, Transfusion, 42, 847, 10.1046/j.1537-2995.2002.00147.x Vamvakas, 2012, Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system, Vox Sang, 102, 302, 10.1111/j.1423-0410.2011.01555.x Cid, 2012, Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials, Vox Sang, 103, 322, 10.1111/j.1423-0410.2012.01614.x